Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort
This real-world study confirms that patients with HR+ BC and unfavorable clinicopathological features are at risk of relapse early in their adjuvant treatment trajectory, despite (neo)adjuvant chemotherapy. It is imperative to implement innovative treatment approaches for high-risk patients, ideally adding them as early as possible to the adjuvant treatment.
Authors
- B. Pistilli
- Fabrice André (ORCID: https://orcid.org/0000-0001-5795-8357)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Federica Giugliano (ORCID: https://orcid.org/0000-0003-3856-5528)
- C. Levy
- Anne‐Laure Martin (ORCID: https://orcid.org/0000-0002-9302-8576)
- Christophe Gaudin (ORCID: https://orcid.org/0000-0002-6326-4551)
- Elie Rassy (ORCID: https://orcid.org/0000-0002-7906-0991)
- Carole Tarpin (ORCID: https://orcid.org/0009-0003-9806-9662)
- Marion Fournier (ORCID: https://orcid.org/0000-0001-5718-1509)
- Alexia Kieffer (ORCID: https://orcid.org/0009-0004-5735-195X)
- Mario Campone (ORCID: https://orcid.org/0000-0002-5196-5908)
- Aurélie Bertaut (ORCID: https://orcid.org/0000-0002-7934-9509)
- Baptiste Sauterey (ORCID: https://orcid.org/0000-0001-9160-7307)
- Julie Blanc (ORCID: https://orcid.org/0000-0002-1542-504X)
- F. Lerebours
- Marie‐Ange Mouret‐Reynier (ORCID: https://orcid.org/0000-0001-5542-5813)
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Centre Georges François Leclerc (FR)
- Institut de Cancérologie de Lorraine (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Hôpital René Huguenin (FR)
- Centre François Baclesse (FR)
- Centre Jean Perrin (FR)
- Institut Bergonié (FR)
- UniCancer Group (FR)
- Institut Paoli-Calmettes (FR)
- European Institute of Oncology (IT)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103994
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Agence Nationale de la Recherche
- Unicancer